BMJ:涨知识:化疗后指甲出现这种白色线条叫“米氏线”!——案例报道

2015-11-16 Seven L 译 MedSci原创

67岁女性患有乳腺癌,在进行第五次辅助化疗前就诊,检查发现患者的指甲发生了如下变化,这是什么变化?什么原因导致指甲的这种改变?指甲上白色的线叫做“米氏线(Mees' lines)”,是由患者的化疗所致。米氏线是博氏线(Beau's lines)的一种变异,表现为手指甲、脚趾甲深沟槽的横向线条。在1919年第一次被荷兰医生R A Mees描述后命名。导致指甲出现米氏线的原因有:肾衰竭;疟疾;砷、铊或

67岁女性患有乳腺癌,在进行第五次辅助化疗前就诊,检查发现患者的指甲发生了如下变化,这是什么变化?什么原因导致指甲的这种改变?



指甲上白色的线叫做“米氏线(Mees' lines)”,是由患者的化疗所致。

米氏线是博氏线(Beau's lines)的一种变异,表现为手指甲、脚趾甲深沟槽的横向线条。在1919年第一次被荷兰医生R A Mees描述后命名。

导致指甲出现米氏线的原因有:肾衰竭;疟疾;砷、铊或其他重金属重度;其他系统性疾病。出现该种变化的机制目前并不清楚。

该患者的化疗间隔时间是21天,手指甲生长速度平均0.1mm/d,一个间隔时间就会表现出两条白线之间距离约为2mm。化疗通常会导致脆甲症,但是出现米氏线还是很少见的,并且如该例如此清楚的米氏线更是罕见。

原始出处:

Thomas Wells.Nail changes.BMJ 2015;351:h6072


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=156149, encodeId=d4ce1561490f, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Nov 16 17:13:18 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803922, encodeId=d452180392218, content=<a href='/topic/show?id=d9bde610122' target=_blank style='color:#2F92EE;'>#米氏线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76101, encryptionId=d9bde610122, topicName=米氏线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed May 25 17:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678390, encodeId=af7616e8390e8, content=<a href='/topic/show?id=a6f85642ebd' target=_blank style='color:#2F92EE;'>#指甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56427, encryptionId=a6f85642ebd, topicName=指甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee927698160, createdName=ycmayy, createdTime=Tue Mar 08 23:52:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847756, encodeId=f228184e75675, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat May 28 18:52:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-11-16 大爰

    学习了增加知识了分享了谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=156149, encodeId=d4ce1561490f, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Nov 16 17:13:18 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803922, encodeId=d452180392218, content=<a href='/topic/show?id=d9bde610122' target=_blank style='color:#2F92EE;'>#米氏线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76101, encryptionId=d9bde610122, topicName=米氏线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed May 25 17:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678390, encodeId=af7616e8390e8, content=<a href='/topic/show?id=a6f85642ebd' target=_blank style='color:#2F92EE;'>#指甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56427, encryptionId=a6f85642ebd, topicName=指甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee927698160, createdName=ycmayy, createdTime=Tue Mar 08 23:52:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847756, encodeId=f228184e75675, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat May 28 18:52:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=156149, encodeId=d4ce1561490f, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Nov 16 17:13:18 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803922, encodeId=d452180392218, content=<a href='/topic/show?id=d9bde610122' target=_blank style='color:#2F92EE;'>#米氏线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76101, encryptionId=d9bde610122, topicName=米氏线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed May 25 17:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678390, encodeId=af7616e8390e8, content=<a href='/topic/show?id=a6f85642ebd' target=_blank style='color:#2F92EE;'>#指甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56427, encryptionId=a6f85642ebd, topicName=指甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee927698160, createdName=ycmayy, createdTime=Tue Mar 08 23:52:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847756, encodeId=f228184e75675, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat May 28 18:52:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-03-08 ycmayy
  4. [GetPortalCommentsPageByObjectIdResponse(id=156149, encodeId=d4ce1561490f, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Nov 16 17:13:18 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803922, encodeId=d452180392218, content=<a href='/topic/show?id=d9bde610122' target=_blank style='color:#2F92EE;'>#米氏线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76101, encryptionId=d9bde610122, topicName=米氏线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed May 25 17:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678390, encodeId=af7616e8390e8, content=<a href='/topic/show?id=a6f85642ebd' target=_blank style='color:#2F92EE;'>#指甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56427, encryptionId=a6f85642ebd, topicName=指甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee927698160, createdName=ycmayy, createdTime=Tue Mar 08 23:52:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847756, encodeId=f228184e75675, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat May 28 18:52:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-28 gaoxiaoe

相关资讯

JAGS:化疗并不能延长老年乳腺癌患者生存期

为了探究化疗疗法的效果,研究人员分别对乳腺癌患者组和结肠癌患者组的患者进行化疗,研究表明:除非进行特殊的联合治疗,否则化疗很可能不会延长80岁以上的乳腺癌患者的寿命;然而,对于结肠癌患者,化疗疗法对89岁以下的老人都有效。德克萨斯大学健康科学中心的研究人员进行了这项研究,并将它发表在《美国老年病学学会杂志》上。研究人员使用了1992-2009年流行病监督及最终结果资料库(SEER)的相关数据,他们

Nature:为何化疗对某些胰腺癌失效了?

近日,刊登于国际著名杂志Nature上的一篇研究论文中,来自德州大学安德森癌症中心的科学家通过研究揭示了为何某些化疗药物,比如吉西他滨不能够有效治疗某些胰腺癌患者,该研究或为开发新型疗法通过增强吉西他滨的功效来阻断肿瘤生长提供希望。 文章中研究者通过对小鼠进行研究发现,抑制一种名为上皮细胞间质转型(EMT)的细胞可塑性过程同吉西他滨的结合或许就

CSCO 2015:陈功:精准医疗时代的个体化结直肠癌辅助化疗

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会在厦门举行。在今天的会议上,来自中山大学肿瘤防治中心的陈功教授做了题为《精准医疗时代的个体化结直肠癌辅助化疗》的报告。以下是陈功教授演讲内容:结直肠癌(colorectal cancer,CRC)是我国最常见的消化道恶性肿瘤之一,而且发病率和死亡率呈上升趋势。据2015年3 月发布的《2015 年中国肿瘤登记年报》数据显示,全国恶性肿瘤发病

Lancet Infect Dis:抗生素耐药性——术后和化疗癌症患者感染死亡率增加的罪魁祸首

背景现如今抗生素的疗效下降不利于病人的治疗过程。出于这一目的,研究人员对十大常见手术中抗生素的使用频率进行了探究,同时对癌症化疗过程中为避免病人出现免疫抑制而预防性使用抗生素等现象进行了深入调查。方式研究人员对相关文献进行了选择,确定了一些随机对照试验和半随机对照试验的荟萃分析和评论,以评估手术中预防性使用抗生素的效果和手术后及癌症化疗后因免疫抑制引起的感染相关性死亡率。研究人员对不同条件下预防性

JCO:地磷莫司治疗晚期子宫内膜癌是有效的,但毒副作用太大

复发或转移性子宫内膜癌女性预后非常差,治疗上的改善迫在眉睫。mTOR通路在该疾病中是很重要的靶位,并且mTOR抑制剂对子宫内膜癌的治疗有效。研究者进行了一项开放、多中心、随机2期试验,比较了口服地磷莫司和黄体酮或化疗(对照组)对复发或转移性子宫内膜癌患者(一二线化疗治疗后疾病进展,同时未进行激素治疗)的疗效情况。初始结局指标为无进展生存期 (PFS) 。该研究共纳入130名患者,其中64名口服地磷

Ann Oncol:厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究)

CTONG-0802,也称OPTIMAL研究首次比较EGFR酪氨酸激酶抑制剂(TKI)厄洛替尼和标准化疗一线治疗EGFR突变晚期非小细胞肺癌(NSCLC)患者的临床效果和耐受性。化疗方案采用吉西他滨+卡铂方案。在前期的PFS研究结果中发现,厄洛替尼显著优于化疗方案,两者PFS分别为13.1个月 [95% CI 10.58-16.53] 和4.6个月 [4.21-5.42](HR:0.16,&nbs